Traws Pharma (TRAW) Times Interest Earned (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Times Interest Earned of -$26.11 for Q1 2026, down 15.93% year-over-year from -$31.06 in Q1 2025, and up 69.88% quarter-over-quarter from -$86.68 in Q4 2025.
Traws Pharma (TRAW) Times Interest Earned (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Times Interest Earned for 13 consecutive years, with -$26.11 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 15.93% year-over-year to -$26.11; the TTM figure through Mar 2026 stood at -$73.75 (up 88.03% YoY), while the FY2025 annual figure was -$0.45, up 88.37% from the prior year.
- Times Interest Earned improved to -$26.11 in Q1 2026 per TRAW's latest filing, from -$86.68 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.03 in Q4 2022 and bottomed at -$5358.0 in Q3 2023.
- Historically, Times Interest Earned has averaged -$525.42 across 5 years, with a median of -$25.21 in 2024.
- Annual changes were most pronounced in 2023 — Times Interest Earned plunged 630339.91% — and 2024, when it jumped 99.9%.
- Traws Pharma's Times Interest Earned stood at -$0.03 in 2022, then sank by 630339.91% to -$212.48 in 2023, then surged by 99.08% to -$1.96 in 2024, then plunged by 4331.02% to -$86.68 in 2025, then surged by 69.88% to -$26.11 in 2026.
- Business Quant data shows TRAW's Times Interest Earned at -$26.11 in Q1 2026, -$86.68 in Q4 2025, and -$23.58 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.11 |
| Dec 31, 2025 | -86.68 |
| Sep 30, 2025 | -23.58 |
| Jun 30, 2025 | -49.96 |
| Mar 31, 2025 | -22.52 |
| Dec 31, 2024 | -1.96 |
| Sep 30, 2024 | -5.33 |
| Mar 31, 2024 | -24.31 |
| Dec 31, 2023 | -212.48 |
| Sep 30, 2023 | -5,357.97 |
| Dec 31, 2022 | -0.03 |
| Mar 31, 2022 | -494.11 |
| Dec 31, 2021 | -0.02 |
| Dec 31, 2020 | -0.04 |
| Mar 31, 2020 | -113.89 |
| Dec 31, 2019 | -184.77 |
| Mar 31, 2019 | -154.06 |
| Dec 31, 2017 | -0.04 |
| Jun 30, 2015 | -6,679.34 |
| Mar 31, 2015 | -12,349.00 |